Quagen Pharmaceuticals
As of the edition of 20 October 2026, Quagen Pharmaceuticals runs 8 drugs, 8 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 8 |
| Total | 8 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Clindamycin | none listed | 0 |
| Betamethasone | none listed | 6 |
| Clobetasol propionate | none listed | 2 |
| Selegiline | none listed | 0 |
| Meperidine | none listed | 1 |
| Clindamycin phosphate | none listed | 0 |
| Betamethasone valerate | none listed | 4 |
| Methenamine | none listed | 0 |
A route B row is one company at one target.